Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: implications for the pathogenesis of HIV-mediated vascular disease.

Human immunodeficiency virus (HIV) infection is associated with accelerated atherosclerosis and vasculopathy, although the mechanisms underlying these findings have not been determined. Hypotheses for these observations include: 1) an increase in the prevalence of established cardiac risk factors observed in HIV-infected individuals who are currently experiencing longer life expectancies; 2) the dyslipidemia reported with certain HIV anti-retroviral therapies; and/or 3) the proinflammatory effects of infiltrating HIV-infected monocytes/macrophages. An unexplored possibility is whether HIV itself can infect vascular smooth muscle cells (SMCs) and, by doing so, whether SMCs can accelerate vascular disease. Our studies demonstrate that human SMCs can be infected with HIV both in vivo and in vitro. The HIV protein p24 was detected by fluorescence confocal microscopy in SMCs from tissue sections of human atherosclerotic plaques obtained from HIV-infected individuals. Human SMCs could also be infected in vitro with HIV by a mechanism dependent on CD4, the chemokine receptors CXCR4 or CCR5, and endocytosis, resulting in a marked increase in SMC secretion of the chemokine CCL2/MCP-1, which has been previously shown to be a critical mediator of atherosclerosis. In addition, SMC proliferation appeared concentric to the vessel lumen, and minimal inflammation was detected, unlike typical atherosclerosis. Our data suggest that direct infection of human arterial SMCs by HIV represents a potential mechanism in a multifactorial paradigm to explain the exacerbated atherosclerosis and vasculopathy reported in individuals infected with HIV.

[1]  J. Berman,et al.  Gap Junctions Mediate Human Immunodeficiency Virus-Bystander Killing in Astrocytes , 2007, The Journal of Neuroscience.

[2]  H. Sørensen,et al.  Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Currier,et al.  Management of antiretroviral treatment-related complications. , 2007, Infectious disease clinics of North America.

[4]  M. Bukrinsky,et al.  Human immunodeficiency virus impairs reverse cholesterol transport from macrophages , 2006, Retrovirology.

[5]  G. Rutherford,et al.  The epidemiology of HIV and AIDS in the world. , 2006, Collegium antropologicum.

[6]  B. Strauss,et al.  Outcome of percutaneous coronary intervention in HIV‐infected patients , 2006, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[7]  B. McManus,et al.  Allograft vasculopathy versus atherosclerosis. , 2006, Circulation research.

[8]  Melissa R Pfeiffer,et al.  Causes of Death among Persons with AIDS in the Era of Highly Active Antiretroviral Therapy: New York City , 2006, Annals of Internal Medicine.

[9]  B. Cotter Endothelial dysfunction in HIV infection , 2006, Current HIV/AIDS reports.

[10]  P. Quax,et al.  Anti–MCP-1 Gene Therapy Inhibits Vascular Smooth Muscle Cells Proliferation and Attenuates Vein Graft Thickening Both In Vitro and In Vivo , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[11]  N. Roudaut,et al.  Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). , 2006, Atherosclerosis.

[12]  K. Sliwa,et al.  Mapping the emergence of heart disease in a black, urban population in Africa: the Heart of Soweto Study. , 2006, International journal of cardiology.

[13]  T. Rabelink,et al.  Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. , 2006, Journal of the American College of Cardiology.

[14]  P. Lozach,et al.  Infection of Dendritic Cells (DCs), Not DC-SIGN-Mediated Internalization of Human Immunodeficiency Virus, Is Required for Long-Term Transfer of Virus to T Cells , 2006, Journal of Virology.

[15]  J. Berman,et al.  Shedding of PECAM‐1 during HIV infection: a potential role for soluble PECAM‐1 in the pathogenesis of NeuroAIDS , 2006, Journal of leukocyte biology.

[16]  S. Lipshultz,et al.  Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. , 2006, Atherosclerosis.

[17]  J. Berman,et al.  CCL2/Monocyte Chemoattractant Protein-1 Mediates Enhanced Transmigration of Human Immunodeficiency Virus (HIV)-Infected Leukocytes across the Blood–Brain Barrier: A Potential Mechanism of HIV–CNS Invasion and NeuroAIDS , 2006, The Journal of Neuroscience.

[18]  R. D. Wiley,et al.  Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Steinman,et al.  HIV-1 Selectively Infects a Subset of Nonmaturing BDCA1-Positive Dendritic Cells in Human Blood1 , 2006, The Journal of Immunology.

[20]  David R. Holtgrave Causes of the decline in AIDS deaths, United States, 1995–2002: prevention, treatment or both? , 2005, International journal of STD & AIDS.

[21]  Leona W Ayers,et al.  AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. , 2005, American journal of physiology. Heart and circulatory physiology.

[22]  S. Grinspoon Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. , 2005, The American journal of medicine.

[23]  J. Esko,et al.  Contribution of Proteoglycans to Human Immunodeficiency Virus Type 1 Brain Invasion , 2004, Journal of Virology.

[24]  P. Gallay Syndecans and HIV-1 pathogenesis. , 2004, Microbes and infection.

[25]  D. Waters,et al.  Clinical Features of Acute Coronary Syndromes in Patients With Human Immunodeficiency Virus Infection , 2004, Circulation.

[26]  M. Marsh,et al.  Infectious HIV-1 assembles in late endosomes in primary macrophages , 2003, The Journal of cell biology.

[27]  S. Venkatesan,et al.  Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. , 2003, Molecular biology of the cell.

[28]  M. Taubman,et al.  Chemokine Receptors in Vascular Smooth Muscle , 2003, Microcirculation.

[29]  J. Berman,et al.  Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. , 2003, Methods.

[30]  F. Diaz-Griffero,et al.  Endocytosis Is a Critical Step in Entry of Subgroup B Avian Leukosis Viruses , 2002, Journal of Virology.

[31]  M. Bukrinsky,et al.  Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Doms,et al.  Evaluation of current approaches to inhibit HIV entry. , 2002, Current drug targets. Infectious disorders.

[33]  M. Prevost,et al.  Human Immunodeficiency Virus Type 1 Entry into Macrophages Mediated by Macropinocytosis , 2001, Journal of Virology.

[34]  M. Galli,et al.  Cardiovascular Disease Risk Factors in HIV‐Infected Patients in the HAART Era , 2001, Annals of the New York Academy of Sciences.

[35]  C. Mcmanus,et al.  HIV envelope gp120 activates human arterial smooth muscle cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[36]  G. Barbarini,et al.  HIV-associated coronary arteritis in a patient with fatal myocardial infarction. , 2001, The New England journal of medicine.

[37]  Z. Xie,et al.  HIV gp120 enhances NO production by cardiac myocytes through p38 MAP kinase-mediated NF-kappaB activation. , 2000, American journal of physiology. Heart and circulatory physiology.

[38]  Y. Bobryshev Identification of HIV-1 in the aortic wall of AIDS patients. , 2000, Atherosclerosis.

[39]  R. Virmani,et al.  Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[40]  Douglas S Kwon,et al.  DC-SIGN, a Dendritic Cell–Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells , 2000, Cell.

[41]  Weixin Zhao,et al.  Human Vascular Smooth Muscle Cells Possess Functional CCR5* , 2000, The Journal of Biological Chemistry.

[42]  R. Loire,et al.  Accelerated coronary atherosclerosis and arteriosclerosis in young human‐immunodeficiency‐virus‐positive patients , 2000, Coronary artery disease.

[43]  J. Weiss,et al.  HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. , 1999, Journal of immunology.

[44]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[45]  P. Libby,et al.  Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. , 1998, Molecular cell.

[46]  B. Rollins,et al.  Tissue Factor Is Induced by Monocyte Chemoattractant Protein-1 in Human Aortic Smooth Muscle and THP-1 Cells* , 1997, The Journal of Biological Chemistry.

[47]  J. Fallon,et al.  Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. , 1997, The Journal of clinical investigation.

[48]  A. Trkola,et al.  Co-receptors for HIV-1 entry. , 1997, Current opinion in immunology.

[49]  P. Luciw,et al.  Transgenic dissection of HIV genes involved in lymphoid depletion. , 1997, The Journal of clinical investigation.

[50]  P. Luciw,et al.  Human immunodeficiency virus-associated vasculopathy in transgenic mice , 1997, Journal of virology.

[51]  Richard T. Lee,et al.  Macrophages and atherosclerotic plaque stability , 1996, Current opinion in lipidology.

[52]  G. Hansson,et al.  Immune mechanisms in atherosclerosis. , 1994, Coronary artery disease.

[53]  Jeani Chang,et al.  Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. , 1993, The American journal of medicine.

[54]  M. Burdick,et al.  Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. , 1992, The Journal of clinical investigation.

[55]  R. Terkeltaub,et al.  Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid. , 1992, The Journal of clinical investigation.

[56]  R. Terkeltaub,et al.  Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. , 1992, Journal of immunology.

[57]  D. Steinberg,et al.  Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[58]  W. Grody,et al.  Infection of the heart by the human immunodeficiency virus. , 1990, The American journal of cardiology.

[59]  M. Kielian,et al.  Mechanisms of enveloped virus entry into cells. , 1990, Molecular biology & medicine.

[60]  L. Highleyman Mortality trends: toward a new definition of AIDS? , 2005, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation.

[61]  G. Whittaker,et al.  Viral entry. , 2005, Current topics in microbiology and immunology.

[62]  R. Doms,et al.  HIV-1 entry and its inhibition. , 2003, Current topics in microbiology and immunology.

[63]  R. Brack-Werner Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. , 1999, AIDS.

[64]  R. Loire,et al.  Coronary artery lesions and human immunodeficiency virus infection. , 1993, Research in virology.